Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas C Blevins

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Clinical Lipidology|October 25, 2018
Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalenceVadzim Chyzhyk, Sarah Kozmic, Alan S Brown, et al.
Nature Medicine|June 24, 2026
Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialJulio Rosenstock, Ildiko Lingvay, Donna Ryan, et al.
Nature Medicine|June 5, 2026
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialJulio Rosenstock, Ildiko Lingvay, Donna Ryan, et al.
Thyroid : Official Journal of the American Thyroid Association|July 6, 2022
Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing ClassifierGregory W Randolph, Julie Ann Sosa, Yangyang Hao, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Clinical Lipidology|October 25, 2018
Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalenceVadzim Chyzhyk, Sarah Kozmic, Alan S Brown, et al.
Nature Medicine|June 24, 2026
Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialJulio Rosenstock, Ildiko Lingvay, Donna Ryan, et al.
Nature Medicine|June 5, 2026
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trialJulio Rosenstock, Ildiko Lingvay, Donna Ryan, et al.
Thyroid : Official Journal of the American Thyroid Association|July 6, 2022
Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing ClassifierGregory W Randolph, Julie Ann Sosa, Yangyang Hao, et al.
Pageof 3